300142 On Other Exchanges
300142 is not on other exchanges.

walvax biotechnology co-a (300142) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WALVAX BIOTECHNOLOGY CO-A (300142)

Related News

No related news articles were found.

walvax biotechnology co-a (300142) Related Businessweek News

No Related Businessweek News Found

walvax biotechnology co-a (300142) Details

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, engages in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It offers bio-medicines, such as vaccines, blood products, and others. The company provides Group A and C meningococcal polysaccharide vaccine for children over the age of 2 years and adults to prevent disease caused by the bacteria named Neisseria meningitidis groups A and group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. It also offers Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, the company provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Founded in 2001

walvax biotechnology co-a (300142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

walvax biotechnology co-a
Walvax Biotechnology Co., Ltd. Proposes Amendments to the Articles of Association

Walvax Biotechnology Co., Ltd. proposed amendments to the articles of association of the company, at its annual general meeting to be held on 10 May 2017.

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2016 Results on Apr 19, 2017

Walvax Biotechnology Co., Ltd. announced that they will report fiscal year 2016 results on Apr 19, 2017

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Dec 27, 2016

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Dec 27, 2016, at 14:00 China Standard Time. Agenda: To consider the appointment of 2016 audit firm; to transfer of 31.65% of equity stake in a company; to sign the agreement on transfer related rights and obligations of the company; and to transfer of 21% of equity stake in another company.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies

Industry Analysis


Industry Average

Valuation 300142 Industry Range
Price/Earnings 100.0x
Price/Sales 30.0x
Price/Book 7.4x
Price/Cash Flow 228.8x
TEV/Sales 21.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.